These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1542 related items for PubMed ID: 30736840

  • 1. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M, Li A, Zhou S, Lv H, Yang W.
    J Hematol Oncol; 2019 Feb 08; 12(1):14. PubMed ID: 30736840
    [Abstract] [Full Text] [Related]

  • 2. Targeting of mutant-p53 and MYC as a novel strategy to inhibit oncogenic SPAG5 activity in triple negative breast cancer.
    Canu V, Vaccarella S, Sacconi A, Pulito C, Goeman F, Pallocca M, Rutigliano D, Lev S, Strano S, Blandino G.
    Cell Death Dis; 2024 Aug 20; 15(8):603. PubMed ID: 39164278
    [Abstract] [Full Text] [Related]

  • 3. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C, Jonnalagadda S, Lingareddy J, Awasthi S, Gmeiner WH, Palle K.
    Breast Cancer Res; 2019 Sep 06; 21(1):104. PubMed ID: 31492187
    [Abstract] [Full Text] [Related]

  • 4. SPAG5 contributes to the progression of gastric cancer by upregulation of Survivin depend on activating the wnt/β-catenin pathway.
    Liu G, Liu S, Cao G, Luo W, Li P, Wang S, Chen Y.
    Exp Cell Res; 2019 Jun 01; 379(1):83-91. PubMed ID: 30904482
    [Abstract] [Full Text] [Related]

  • 5. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H, Lee DH, Ding L, Sun H, Gery S, de Gramont A, Koeffler HP.
    Biomed Pharmacother; 2018 Mar 01; 99():543-551. PubMed ID: 29902865
    [Abstract] [Full Text] [Related]

  • 6. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC, Wang JX, Han ML, Zhang LP, Li L.
    Cell Oncol (Dordr); 2017 Apr 01; 40(2):157-166. PubMed ID: 28054302
    [Abstract] [Full Text] [Related]

  • 7. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ.
    Breast Cancer Res; 2015 Mar 07; 17():33. PubMed ID: 25888415
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K.
    Cancer Res; 2018 Feb 01; 78(3):742-757. PubMed ID: 29180466
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA.
    BMC Cancer; 2015 Mar 03; 15():89. PubMed ID: 25884663
    [Abstract] [Full Text] [Related]

  • 13. MiR-26b-5p inhibits cell proliferation and EMT by targeting MYCBP in triple-negative breast cancer.
    Ma S, Wei H, Wang C, Han J, Chen X, Li Y.
    Cell Mol Biol Lett; 2021 Dec 11; 26(1):52. PubMed ID: 34895159
    [Abstract] [Full Text] [Related]

  • 14. SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.
    Yuan LJ, Li JD, Zhang L, Wang JH, Wan T, Zhou Y, Tu H, Yun JP, Luo RZ, Jia WH, Zheng M.
    Cell Death Dis; 2014 May 22; 5(5):e1247. PubMed ID: 24853425
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M, Li AQ, Zhou SL, Lv H, Wei P, Yang WT.
    J Exp Clin Cancer Res; 2020 May 24; 39(1):92. PubMed ID: 32448269
    [Abstract] [Full Text] [Related]

  • 18. METTL3 orchestrates glycolysis by stabilizing the c-Myc/WDR5 complex in triple-negative breast cancer.
    Yuan XN, Shao YC, Guan XQ, Liu Q, Chu MF, Yang ZL, Li H, Zhao S, Tian YH, Zhang JW, Wei L.
    Biochim Biophys Acta Mol Cell Res; 2024 Jun 24; 1871(5):119716. PubMed ID: 38547933
    [Abstract] [Full Text] [Related]

  • 19. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
    Ye L, Li F, Song Y, Yu D, Xiong Z, Li Y, Shi T, Yuan Z, Lin C, Wu X, Ren L, Li X, Song L.
    Int J Cancer; 2018 Nov 15; 143(10):2602-2613. PubMed ID: 30151890
    [Abstract] [Full Text] [Related]

  • 20. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H, Wu T, Xie D, Li D, Hua K, Hu J, Fang L.
    Cell Physiol Biochem; 2018 Nov 15; 48(5):1968-1982. PubMed ID: 30092563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.